Amolimogene
- Generic Name
- Amolimogene
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 676269-70-8
- Unique Ingredient Identifier
- 8B5KCA0GAK
- Background
Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
- Indication
Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT00264732
- Locations
- 🇺🇸
Physician Care Clinical Research, Sarasota, Florida, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Visions Clinical Research, Boynton Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath